Acquisition Momentum CareMetx recently expanded its patient access platform through the acquisition of Cencora’s US-based patient services and free goods pharmacy operations, signaling a growth wave and potential cross-sell opportunities to integrate these assets with your existing pharmaceutical and biotech clients.

Leadership & Strategy The appointment of Greg Morris as President and Chief Strategy Officer in 2026 and new C-suite roles in 2025–2026 indicate a strategic emphasis on scale, partnerships, and go-to-market execution, suggesting readiness for new enterprise collaborations and broader service engagements.

Platform Upgrades Launching a next-generation patient access platform in early 2026 demonstrates a focus on technology-driven patient services, offering a compelling case for co-development or integration partnerships with drug manufacturers seeking advanced patient access and adherence solutions.

Strategic Partnerships Active collaboration with Syneos Health and participation in industry events like Informa Connect Access USA 2026 point to a preference for ecosystem partnerships, presenting a pathway to joint offerings, channel partnerships, and referrals to broader biopharma client bases.

Financial Scale With revenue in the 500M to 1B range and a sizeable employee base, CareMetx represents a mid-market scale partner capable of handling large, multi-brand programs for specialty therapies, offering stability and capacity for expanded, multi-year engagements.